April 2011 – According to a recent article published by Businessweek, men who undergo androgen-deprivation therapy are 50 percent less likely to die from prostate cancer than men who don’t. Androgen-deprivation therapy is a type of male hormone therapy that reduces levels of testosterone – the male hormone that accelerates the growth of prostate cancer cells.
Dr. David Lamb and his research team randomly assigned 802 men diagnosed with locally advanced prostate cancer to either radiation, three months of hormone therapy with radiation, or six months of hormone therapy with radiation. The researchers found that men who used hormone therapy for a period of six months in conjunction with radiation treatment were significantly less likely to die from prostate cancer than men who used radiation by itself. The men were also less likely to die from any other causes.
The research team also notes that using androgen-deprivation therapy for a period that extends beyond six months could result in serious side effects, including hot flashes, fatigue, erectile dysfunction, high cholesterol, anemia and even cardiac death.
Read the full article: Short Course of Hormone Therapy Boosts Prostate Cancer Survival